IMP4297 DDI (Drug-Drug Interaction)Trial in Healthy Male Volunteers

NCT ID: NCT04584515

Last Updated: 2021-08-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 32 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-11-02
• Study Completion Date: 2021-05-27

Brief Summary

A Phase I, Open-label, Fixed-Sequence Study to Evaluate the Effect of Multiple-dose Itraconazole or Rifampicin Capsules on the Single-dose PK Profiles of IMP4297 Capsules in Healthy Subjects

Detailed Description

Study design A Phase I, single-center, open-label, fixed-sequence study is designed to evaluate the effect of multiple-dose Itraconazole or Rifampicin Capsules on the single-dose PK profiles of IMP4297 Capsules in healthy Chinese subjects.

32 subjects are planned to be enrolled (at least 12 subjects complete the study on one side).

Two parallel groups will be planned in this study with 16 subjects enrolled in each group. Two cycles are set for each group. The first group will be given IMP4297 and Itraconazole in a fixed sequence (two dosing regimens); The second group will receive IMP4297 and Rifampicin in a fixed sequence (two dosing regimens).

Conditions

Solid Tumor

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

IMP4297 40 mg

Sequential treatments of IMP4297 alone, followed by Itraconazole + IMP4297, with a washout period in between.

Group Type: EXPERIMENTAL

IMP4297 40 mg

Intervention Type: DRUG

IMP4297 40 mg: IMP4297 alone, Itraconazole + IMP4297

IMP4297 100 mg

Sequential treatments of IMP4297 alone, followed by Rifampin + IMP4297, with a washout period in between.

Group Type: EXPERIMENTAL

IMP4297 100 mg

Intervention Type: DRUG

IMP4297 100 mg: IMP4297 alone, Rifampin + IMP4297

Interventions

IMP4297 40 mg

IMP4297 40 mg: IMP4297 alone, Itraconazole + IMP4297

Intervention Type: DRUG

IMP4297 100 mg

IMP4297 100 mg: IMP4297 alone, Rifampin + IMP4297

Intervention Type: DRUG

Other Intervention Names

Itraconazole; Rifampin

Eligibility Criteria

Inclusion Criteria

1. Subjects fully understand the purpose, nature, methods and possible adverse reactions of the trial, voluntarily participate in the trial, and sign an informed consent form before any trial procedure, and promise to participate in all procedure of the trial.

2. Healthy Chinese male subjects aged 18 to 55 (inclusive) at the time of signing informed consent form.

3. Body mass index (BMI) ranges from 19.0 to 26.0 kg/m2 (inclusive); body weight ≥ 50.0 kg.

4. Subjects can communicate well with the investigators and understand and abide by the requirements of this trial.

Exclusion Criteria

1. Subjects with past and present diseases with clinical abnormality in the opinion of the investigator, including but not limited to disease concerning nervous system, cardiovascular system, blood and lymphatic system, immune system, kidney, liver, gastrointestinal tract, respiratory system, metabolic system and skeletal system;

2. Subjects with allergic history (including drug and food allergies, etc.).

3. Subjects with history of dysphagia or any gastrointestinal disease that affects drug absorption judged by the investigator.

4. Subjects who have received surgery within 3 months before screening, or plan to have surgery during the trial period, or those who had surgery that will affects drug absorption (e.g. gastrectomy).

5. Subjects who cannot tolerate venipuncture, or have a history of needlesickness and fainting at the sight of blood.

6. Subject with lactose intolerability (who having had milk diarrhea).

7. Subjects who have drug abuse history within 6 months before screening, or have a positive urine drug screening (screening or baseline period) result.

8. Subjects who have used narcotics within 3 months before screening.

9. Subjects who consumed an average of more than 14 units of alcohol per week (1 unit of alcohol = 360 mL beer, 150 mL wine, or 45 mL liquor) within 3 months before screening, or who had a positive result of alcohol breath test (screening or baseline period), or could not give up alcohol during the trial.

10. Subjects who consumed an average of more than 5 cigarettes per day within 3 months before screening, or who could not stop using any tobacco products during the trial.

11. Subjects who consumed an average of excessive amounts of tea, coffee and / or caffeinated beverages (more than 8 cups, 1 cup = 250 mL) every day within 3 months before screening.

12. Subjects who have participated in clinical trials of other study drugs/devices within 3 months before the first dose of the investigational drug, or have participated in 3 or more clinical trials of drugs/devices in the past year; if other study drugs have a longer half-life, the time interval will be longer and is required to be 5 half-lives of the drug.

13. Subjects who donated blood including blood component or have massive blood loss (2,200 mL), or received blood transfusion or used blood products within 3 months before screening.

14. Subjects who received vaccination within 4 weeks before screening.

15. Subjects who have taken any drugs [such as: barbiturates, carbamazepine, phenytoin, glucocorticoids, omeprazole; SSRI antidepressants, cimetidine, macrolides, nitroimidazoles, sedative hypnotics, fluoroquinolones, antihistamines, antivirals (such as saquinavir), calcium antagonists (such as diltiazem, verapamil), rifamycins (such as rifampin)] that inhibit or induce the liver to metabolize drug within 28 days before the first dose of the investigational drug. If the past drug used has a longer half-life, the time interval will be longer and is required to be 5 half-lives of the drug, eg, Phenobarbital requires a 5-week washout period.

16. Subjects who have taken prescription drugs, over-the-counter drugs, dietary supplements or Chinese herbal medicine within 14 days before the first dose of the investigational drug. If the past drug used has a longer half-life, the time interval will be longer and is required to be 5 half-lives of the drug.

17. Any test result of hepatitis B surface antigen, hepatitis C virus antibody, human immunodeficiency virus (HIV) antibody, or treponema pallidum antibody is positive.

18. At screening, vital signs (blood pressure, pulse and body temperature) examination, comprehensive physical examination and laboratory tests (hematology, blood biochemistry, urinalysis) indicate abnormal results with clinical significance according to the investigator. The reference normal range of vital signs (including the cut-off value) is as follows: Sitting systolic blood pressure is 90 to 139 mmHg, diastolic blood pressure is 60 to 89 mmHg, pulse is 50 to 100 bmp, body temperature (frontal temperature) is 36.0 to 37.0°C. The specific situation is comprehensively determined by the investigator.

19. At screening after a quiet rest for at least 10 min, the corrected QT interval (corrected by Fridericia's formula, QTcF = QT/RR1/3) > 450 msec or QRS complex > 120 msec was obtained by 12-lead ECG in supine position. If QTcF is more than 450 msec or QRS is more than 120 msec, 12-lead ECG measurement should be repeated twice, and the average value of QTcF or QRS measured three times is judged by the investigator as abnormality with clinical significance.

20. Subjects who are allergic to IMP4297, Itraconazole, Rifampicin, or to any ingredients of these preparations.

21. Vigorous exercise cannot be avoided within 48 hours before the first dose of the investigational drug and during the trial.

22. Subjects who consumed any food or beverages containing alcohol, caffeine, chocolate, or rich in xanthine within 48 hours before the first dose of the investigational drug; or those who cannot abstain from these products during the trial.

23. Subjects who cannot abstain from grapefruit or grapefruit-related citrus (eg, pomelo) or juice within 7 days before the first dose of investigational drug and during the trial;

24. Subjects or its partners who have birth plan, or are unwilling to adopt effective contraception methods (Annex 2), or have sperm donation plan throughout the trial and within 180 days after the last dose of the investigational drug.

25. Subjects who are unwilling or unable to follow the lifestyle guidelines described in the study protocol (such as dietary restrictions and activity requirements).

26. Subjects who have other acute or chronic medical or psychiatric diseases, which may increase the risks of participating in this trial, or may interfere with the interpretation of the trial results, will be judged unsuitable to participate in this trial by the investigator.

27. Subjects judged by the investigator to be unsuitable for participation in the trial.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Impact Therapeutics, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Pingsheng Xu

Role: PRINCIPAL_INVESTIGATOR

Xiangya Hospital of Central South University

Locations

Impact Therapeutics, Inc.

Shanghai, , China

Countries

China

References

Hu X, Hsieh CY, Zhang Y, Liu W, Xu S, Cai SX, Liu L, Zhang M, Shi H, Zhang H, Liu P, Li X, Xu P. Effect of a strong CYP3A4 inhibitor and inducer on the pharmacokinetics of senaparib (IMP4297) in healthy volunteers: A drug-drug interaction study. Br J Clin Pharmacol. 2023 Jun;89(6):1767-1779. doi: 10.1111/bcp.15624. Epub 2023 Jan 3.

Reference Type: DERIVED

PMID: 36458825 (View on PubMed)

Other Identifiers

IMP4297-104

Identifier Type: -

Identifier Source: org_study_id